续苓健骨方对去卵巢骨质疏松模型大鼠血液钙磷代谢的影响
|
摘要
目的研究续苓健骨方对去卵巢骨质疏松模型大鼠骨密度、骨微结构和血液钙磷代谢的影响。方法将40只6月龄雌性SD大鼠随机分为假手术组、模型组、续苓健骨方组[12.71 g/(kg·d)]和碳酸钙组[104.19 mg/(kg·d)],假手术组仅切除卵巢周围脂肪,其余组行双侧卵巢切除术后建立骨质疏松模型。药物干预12周后取材,通过双能X线骨密度仪检测左侧胫骨骨密度,经Masson染色观察右侧胫骨组织显微结构,生化检测血清抗酒石酸酸性磷酸酶(TRAP)、血钙和血磷水平。结果与假手术组相比,模型组骨密度显著降低,骨小梁断裂稀疏、排列不规则,TRAP表达增加,血钙含量降低,血磷含量升高。与模型组相比,续苓健骨方组骨密度增加,骨小梁数量增加、排列较规则,TRAP表达降低,血钙含量升高,血磷含量降低。结论续苓健骨方可提高去卵巢骨质疏松大鼠胫骨骨密度并改善骨组织微结构,其机制可能与调控血钙磷代谢稳态有关。
Objective To study the effects of Xuling jiangu prescription on bone mineral density(BMD), bone microstructure and blood calcium and phosphorus metabolism in ovariectomized osteoporosis model rats. Methods Forty female 6-month-old SD rats were randomly divided into 4 groups: sham operation group, model group, Xuling jiangu prescription group [12.71 g/(kg·d)] and calcium carbonate group [104.19 mg/(kg· d) ], the sham operation group only had fat around the ovary removed, and the other group underwent bilateral ovariectomy to establish a model of osteoporosis. After 12 weeks of drug intervention, BMD of the left tibia was detected by dual-energy X-ray absorptiometry. The microstructure of the right tibia was observed by Masson staining. Tartrate resistant acid phosphatase, serum calcium and serum phosphorus were detected by serum biochemistry. Results Compared with the sham group, the BMD of the model group was significantly decreased, the trabecular bone was fractured, sparse and irregularly arranged, the expression of TRAP increased, the serum calcium content decreased and the serum phosphorus content increased. Compared with the model group, the BMD of the Xuling jiangu group increased, the number of trabecular bone increased and the arrangement was regular, the expression of TRAP decreased, the serum calcium content increased, and the blood phosphorus content decreased. Conclusion Xuling jiangu prescription can improve BMD of the tibia of ovariectomized osteoporosis rats and improve the microstructure of the bone tissue. Its mechanism may be related to the regulation of serum calcium and phosphorus metabolism steady state.
Objective To study the effects of Xuling jiangu prescription on bone mineral density(BMD), bone microstructure and blood calcium and phosphorus metabolism in ovariectomized osteoporosis model rats. Methods Forty female 6-month-old SD rats were randomly divided into 4 groups: sham operation group, model group, Xuling jiangu prescription group [12.71 g/(kg·d)] and calcium carbonate group [104.19 mg/(kg· d) ], the sham operation group only had fat around the ovary removed, and the other group underwent bilateral ovariectomy to establish a model of osteoporosis. After 12 weeks of drug intervention, BMD of the left tibia was detected by dual-energy X-ray absorptiometry. The microstructure of the right tibia was observed by Masson staining. Tartrate resistant acid phosphatase, serum calcium and serum phosphorus were detected by serum biochemistry. Results Compared with the sham group, the BMD of the model group was significantly decreased, the trabecular bone was fractured, sparse and irregularly arranged, the expression of TRAP increased, the serum calcium content decreased and the serum phosphorus content increased. Compared with the model group, the BMD of the Xuling jiangu group increased, the number of trabecular bone increased and the arrangement was regular, the expression of TRAP decreased, the serum calcium content increased, and the blood phosphorus content decreased. Conclusion Xuling jiangu prescription can improve BMD of the tibia of ovariectomized osteoporosis rats and improve the microstructure of the bone tissue. Its mechanism may be related to the regulation of serum calcium and phosphorus metabolism steady state.
引文
[1] Black DM, Rosen CJ. Postmenopausal osteoporosis[J]. N Engl JMed, 2016, 374(21):2096-2097.
[2] Cosman F, de Beur SJ, LeBoff SF, et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis[J].Osteoporos Int, 2014, 25(10): 2359-2381.
[3] Rongtao Cui, Lin Zhou, Zuohong Li, et al. Assessment risk of osteoporosis in Chinese people: relationship among body mass index, serum lipid profiles, blood glucose, and bone mineral density[J].Clin Interv Aging, 2016(11): 887-895.
[4] Redmond J, Jarjou LM, Zhou B, et al. Ethnic differences in calcium, phosphate and bone metabolism[J]. Proc Nutr Soc, 2014,73(2):340-351.
[5] Mathavan N, Turunen MJ, T?gil M, et al. Characterising bone material composition and structure in the ovariectomized (OVX) rat model of osteoporosis[J]. Calcif Tissue Int, 2015, 97(2):134-144.
[6] Zhu K, Prince RL. Calcium and bone[J]. Clin Biochem, 2012, 45(12):936-942.
[7] Vaishali V,Ran W, Leyla O, et al. Vitamin D, calcium homeostasis and aging[J]. Bone Res, 2016,4: 16041.
[8] Calvo MS, Tucker KL. Is phosphorus intake that exceeds dietary requirements a risk factor in bone health? [J] Ann N Y Acad Sci, 2013,1301:29-35.
[9] Kovacs CS. Bone development and mineral homeostasis in the fetus and neonate: roles of the calciotropic and phosphotropic hormones[J]. Physiol Rev, 2014, 94(4):1143-1218.
[10] Christakos S. Recent advances in our understanding of 1,25-dihydroxyvitamin D(3) regulation of intestinal calcium absorption[J]. Arch Biochem Biophys, 2012,523(1): 73-76.
[11] Khundmiri SJ, Murray RD, Lederer E. PTH and Vitamin D[J]. Compr Physiol,2016, 6(2):561-601.
[12] James C. Fleet, Ryan D. Schoch. Molecular Mechanisms for Regulation of Intestinal Calcium Absorption by Vitamin D and Other Factors[J]. Crit Rev Clin Lab Sci, 2010, 47(4):181-195.
[13] Lee KJ, Kim KS, Kim HN, et al. Association between dietary calcium and phosphorus intakes, dietary calcium/phosphorus ratio and bone mass in the Korean population[J]. Nutr J, 2014,13(1): 114.
[14] Anderson J, Adatorwovor R, Roggenkamp K, et al. Lack of Influence of Calcium/Phosphorus Ratio on Hip and Lumbar Bone Mineral Density in Older Americans: NHANES 2005-2006 Cross-Sectional Data[J]. J Endocr Soc, 2017, 1(5): 407-414.
[15] 章轶立,唐彬,姜俊杰,等.整合药理学视角下的骨碎补治疗骨质疏松症作用机制研究[J].中国中药杂志,2018:1-9.
[16] 肖洪贺,郭周全,郑彧,等.茯苓不同提取部位对小鼠胃肠运动功能的抑制作用研究[J].中国现代中药,2017,19(5):679-683,705.
[17] 孙晓雨,崔子寅,张明亮,等.枸杞多糖和茯苓多糖对免疫抑制小鼠免疫增强及对肠道黏膜的免疫调节作用[J].中国兽医学报,2015,35(3):450-455.
[18] 张明发,沈雅琴.女贞子及其活性成分抗骨质疏松症的研究进展[J].药物评价研究,2014,37(6):566-571.
[19] Zhao JG, Zeng XT, Wang J, et al. Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults: A Systematic Review and Meta-analysis[J].JAMA,2017, 318(24):2466-2482.
[20] Eriksen EF, Díez-Pérez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review[J]. Bone, 2014,58:126-135.
[21] Lim SY, Bolster MB. Current approaches to osteoporosis treatment[J]. Curr Opin Rheumatol, 2015, 27(3):216-224.
[22] Tsai JN, Nishiyama KK, Lin D, et al. Effects of Denosumab and Teriparatide Transitions on Bone Microarchitecture and Estimated Strength: the DATA-Switch HR-pQCT study[J]. J Bone Miner Res, 2017, 32(10):2001-2009.
[2] Cosman F, de Beur SJ, LeBoff SF, et al. Clinician’s Guide to Prevention and Treatment of Osteoporosis[J].Osteoporos Int, 2014, 25(10): 2359-2381.
[3] Rongtao Cui, Lin Zhou, Zuohong Li, et al. Assessment risk of osteoporosis in Chinese people: relationship among body mass index, serum lipid profiles, blood glucose, and bone mineral density[J].Clin Interv Aging, 2016(11): 887-895.
[4] Redmond J, Jarjou LM, Zhou B, et al. Ethnic differences in calcium, phosphate and bone metabolism[J]. Proc Nutr Soc, 2014,73(2):340-351.
[5] Mathavan N, Turunen MJ, T?gil M, et al. Characterising bone material composition and structure in the ovariectomized (OVX) rat model of osteoporosis[J]. Calcif Tissue Int, 2015, 97(2):134-144.
[6] Zhu K, Prince RL. Calcium and bone[J]. Clin Biochem, 2012, 45(12):936-942.
[7] Vaishali V,Ran W, Leyla O, et al. Vitamin D, calcium homeostasis and aging[J]. Bone Res, 2016,4: 16041.
[8] Calvo MS, Tucker KL. Is phosphorus intake that exceeds dietary requirements a risk factor in bone health? [J] Ann N Y Acad Sci, 2013,1301:29-35.
[9] Kovacs CS. Bone development and mineral homeostasis in the fetus and neonate: roles of the calciotropic and phosphotropic hormones[J]. Physiol Rev, 2014, 94(4):1143-1218.
[10] Christakos S. Recent advances in our understanding of 1,25-dihydroxyvitamin D(3) regulation of intestinal calcium absorption[J]. Arch Biochem Biophys, 2012,523(1): 73-76.
[11] Khundmiri SJ, Murray RD, Lederer E. PTH and Vitamin D[J]. Compr Physiol,2016, 6(2):561-601.
[12] James C. Fleet, Ryan D. Schoch. Molecular Mechanisms for Regulation of Intestinal Calcium Absorption by Vitamin D and Other Factors[J]. Crit Rev Clin Lab Sci, 2010, 47(4):181-195.
[13] Lee KJ, Kim KS, Kim HN, et al. Association between dietary calcium and phosphorus intakes, dietary calcium/phosphorus ratio and bone mass in the Korean population[J]. Nutr J, 2014,13(1): 114.
[14] Anderson J, Adatorwovor R, Roggenkamp K, et al. Lack of Influence of Calcium/Phosphorus Ratio on Hip and Lumbar Bone Mineral Density in Older Americans: NHANES 2005-2006 Cross-Sectional Data[J]. J Endocr Soc, 2017, 1(5): 407-414.
[15] 章轶立,唐彬,姜俊杰,等.整合药理学视角下的骨碎补治疗骨质疏松症作用机制研究[J].中国中药杂志,2018:1-9.
[16] 肖洪贺,郭周全,郑彧,等.茯苓不同提取部位对小鼠胃肠运动功能的抑制作用研究[J].中国现代中药,2017,19(5):679-683,705.
[17] 孙晓雨,崔子寅,张明亮,等.枸杞多糖和茯苓多糖对免疫抑制小鼠免疫增强及对肠道黏膜的免疫调节作用[J].中国兽医学报,2015,35(3):450-455.
[18] 张明发,沈雅琴.女贞子及其活性成分抗骨质疏松症的研究进展[J].药物评价研究,2014,37(6):566-571.
[19] Zhao JG, Zeng XT, Wang J, et al. Association Between Calcium or Vitamin D Supplementation and Fracture Incidence in Community-Dwelling Older Adults: A Systematic Review and Meta-analysis[J].JAMA,2017, 318(24):2466-2482.
[20] Eriksen EF, Díez-Pérez A, Boonen S. Update on long-term treatment with bisphosphonates for postmenopausal osteoporosis: a systematic review[J]. Bone, 2014,58:126-135.
[21] Lim SY, Bolster MB. Current approaches to osteoporosis treatment[J]. Curr Opin Rheumatol, 2015, 27(3):216-224.
[22] Tsai JN, Nishiyama KK, Lin D, et al. Effects of Denosumab and Teriparatide Transitions on Bone Microarchitecture and Estimated Strength: the DATA-Switch HR-pQCT study[J]. J Bone Miner Res, 2017, 32(10):2001-2009.